Kynureninase induce cuproptosis resistance in gastric cancer progression through downregulating lipotic acid synthetase mediated non-canonical mechanism
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Kynureninase (KYNU) promotes gastric cancer progression and resistance to cuproptosis, a cell death pathway. This occurs by downregulating lipoic acid synthetase (LIAS), independent of its metabolite 3-HA.
Area Of Science
- Oncology
- Molecular Biology
- Cell Death Mechanisms
Background
- Gastric cancer (GC) is a highly lethal malignancy with poor prognosis and limited therapeutic options.
- Kynureninase (KYNU), a key enzyme in tryptophan metabolism, is implicated in promoting tumor progression and immune suppression.
- Cuproptosis, a copper-induced cell death pathway, is linked to tumor progression and drug resistance.
Purpose Of The Study
- To investigate the role of KYNU in regulating gastric cancer biological behavior and cuproptosis.
- To elucidate the underlying molecular mechanisms by which KYNU influences GC progression and cell death pathways.
Main Methods
- Analysis of KYNU expression and prognostic significance in GC using The Cancer Genome Atlas and clinical specimens.
- In vitro assays (CCK8, clone formation, Transwell, flow cytometry) to assess KYNU's effects on GC cell proliferation, invasion, metastasis, and cuproptosis.
- Investigating the role of lipoic acid synthetase (LIAS) in mediating KYNU's effects through gene manipulation.
Main Results
- KYNU is significantly overexpressed in GC tissues and serves as an independent predictor of poor prognosis.
- High KYNU expression correlates with increased GC cell proliferation, invasion, metastasis, and resistance to cuproptosis.
- KYNU promotes these effects by downregulating LIAS expression, independent of its metabolite 3-hydroxyanthranilic acid (3-HA).
Conclusions
- KYNU plays a critical role in promoting gastric cancer progression, invasion, metastasis, and resistance to cuproptosis.
- The mechanism involves the downregulation of LIAS, a key cuproptosis-related gene, rather than through its metabolite 3-HA.
- Targeting KYNU or LIAS may represent a novel therapeutic strategy for gastric cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...